AC Immune is planning to advance its investigational anti-TDP-43 antibody into clinical testing for neurodegenerative diseases in which TPD-43 protein aggregates play a major role in brain damage, including diseases such as Alzheimer’s, amyotrophic lateral sclerosis, and frontotemporal lobar degeneration with TDP-43 pathology.
XPro1595, an investigational therapy by INmune Bio, can lower brain inflammation in people with mild to moderate Alzheimer’s disease, according to interim results of a clinical trial. Specifically, the Phase 1b clinical trial (NCT03943264) shows evidence that XPro1595 decreases white matter free water, a biomarker…
The U.S. Food and Drug Administration (FDA) has accepted and given priority review designation to Biogen‘s application requesting the approval of aducanumab (BIIB037) for the treatment of Alzheimer’s disease. While the Prescription Drug User Fee Act (PDUFA) action date is set for…
Testing of a second and higher dose of ACI-35.030, a potential Alzheimer’s vaccine, is now beginning in a Phase 1b/2a clinical trial, AC Immune announced. Positive interim safety, tolerability, and specificity results from an initial dosing group of patients allowed the trial to advance to its medium…
Vaccines against the flu and pneumonia are associated with a lower risk of developing Alzheimer’s disease, while infections are generally linked to increased mortality among people with dementia, according to three research studies presented at this year’s Alzheimer’s Association International Conference, which is being held virtually this…
The U.S. Food and Drug Administration (FDA) has accepted a request by Acadia Pharmaceuticals‘ that  Nuplazid (pimavanserin) be approved for a new indication: the treatment of delusions and hallucinations associated with dementia-related psychosis. The company’s supplemental new drug application, which was submitted in June, was granted…
BAN2401, an experimental treatment for Alzheimer’s disease (AD), will be tested in the new global AHEAD 3-45 clinical trial, its developers have announced. The Phase 3 study — to be conducted in the U.S., Canada, Japan,…
The Alzheimer’s Foundation of America (AFA) is expanding the availability of its National Toll-Free Helpline — adding weekend hours as well as chat and message features in dozens of languages — to provide greater support to patients and family members. The resource’s hours now are 9 a.m. to…
Biogen and Eisai have submitted a biologics license application (BLA) to the U.S. Food and Drug Administration (FDA) requesting the approval of aducanumab (BIIB037) for the treatment of Alzheimer’s disease. The submission, which was asking for priority review, had been pushed…
To promote brain health, the Alzheimer’s Foundation of America (AFA) is offering free online memory screenings that people can participate in from home. The confidential screenings — part of the AFA’s National Memory Screening Program — are provided Mondays and Wednesdays from 10…
Get regular updates to your inbox.